CLIENT AGGREGATION SERVICES

MASS TORT ALERT

For client aggregation assistance, contact (210) 635-0468 or info@masstortamerica.com.

Predicted Mass Tort Action:

Benicar® (olmesartan) hypertension (high blood pressure)

Potential Defendant(s)

• Primary: Daiichi Sankyo Co., LTD. (4568.TYO); Forest Laboratories, Inc. (FRX).

Primary Defendant Financial Data: Revenues for the full year 2010 of ¥952.1B.

As of March 31, 2010, Daiichi Sankyo had 100 subsidiaries and four associated

companies.

• Secondary: Prescribing Physicians, Testing Laboratories, and other entities in the

distribution chain. Financial Condition Varies, Mostly Insured.

Potential Plaintiffs

Individuals prescribed Benicar®.

Potential Plaintiff Numerosity

Potentially, any of the 900+ million adults worldwide estimated to suffer from

hypertension who may have been prescribed Benicar®.

Potential Plaintiff Claims

Wrongful Death, Permanent Disability, Life-Threatening Permanent Injury, Medical

Malpractice, Defective Product, Failure to adequately warn of risks.

Potential Cause of Action

Manufacturer, physicians and marketing materials may have failed to properly inform

diabetes patients of the risk of permanent injury and death associated with Benicar®

use. The FDA has issued a Warning Letter to the manufacturer for “false or misleading”

product promotion.

Aggravating Circumstance: FDA approved Benicar® in 2002. Two clinical trials

(ROADMAP and ORIENT), indicating the drug may increase the risk of death in patients

with diabetes, is not completed until 2009. During this time, Benicar® is heavily promoted and prescribed for patients with hypertension. In 2010, the FDA announces

“Ongoing Safety Review” of the 2009 clinical trials where patients had “a higher rate of

death from a cardiovascular cause compared to patients taking a placebo.”

Client Origination and Aggregation Challenges

Most of the potential plaintiffs injured by prescription use of Benicar® may not be aware

that Benicar® has caused their injury or the death of their loved one. Although

mainstream media coverage is expected in this case, the issue has yet to be broadly

published in the media and the prescribing physicians are unlikely to inform the injured

patients or patient’s family that the prescription they wrote caused the injury or death.

*Contact us to discuss our client aggregation services (210) 635-0468

info@masstortamerica.com.

Opportunity

The opportunity to be the originator of a mass or class action exists in this issue. Premedia

exposure knowledge of these circumstances presents a unique opportunity for a

plaintiff law firm. *Contact us to discuss our client aggregation services (210) 635-0468

info@masstortamerica.com.

Client Generation Strategy

Internet search engine domination followed by mass press release. This two-pronged

strategy should be sufficient to aggregate a significant number of plaintiffs. Other forms

of advertising including television could be indicated if justified by the plaintiff volume

acquired in the initial plaintiff aggregation phase. *Contact us to discuss our client

aggregation services (210) 635-0468 info@masstortamerica.com.

Disclaimer

If you are not an Attorney this information is not intended for you. If you need legal help,

please seek the advice of an Attorney. If you need medical help, please seek the advice

of a Medical Doctor. No one should discontinue the use of any medication without

seeking the advice of a Medical Doctor.

The information provided in this alert is not intended to be legal advice. This alert is

provided directly to practicing attorneys and is for the sole use of those attorneys.

Further dissemination of this alert is prohibited. It is assumed that the receiving attorney

has the ability to conduct independent research on the information provided and does

not need to rely solely on the provided information for any purpose.

Benicar® is a registered trademark of Daiichi Sankyo, Inc. Mass Tort America is not

affiliated with Benicar ® or Daiichi Sankyo, Inc.

References

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm215249.htm

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054388.pdf

http://investing.businessweek.com/businessweek/research/stocks/earnings/earnings.asp?ticker=4568:JP

http://www.google.com/finance?q=TYO:4568

http://www.ncbi.nlm.nih.gov/pubmed/15652604

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NMEDrugandNewBiologicApprovals/ucm081683.htm

http://www.reuters.com/article/idUSN1113920620100611

http://www.theheart.org/article/1087567.do

http://www.daiichisankyo.com/

http://www.google.com/finance?q=TYO:4568

http://www.frx.com/

http://www.benicar.com/

http://www.dsi.com/

Benicar Lawyers

Benicar Lawyers – If you are a law firm working with victims of the drug Benicar and would like to add your content to this website, please email us at info@masstortamerica.com or you can use our contact form on this page. Benicar Lawyersare needed to protect the rights of the victims of Benicar.

This blog is intended to bring information to the public about Benicar and help indiviuals get information from a Benicar Lawyer. Our primary focus is to address how those effected by Benicar can seek to recover from the devastation this drug has inflicted in their lives. Although no amount of financial recovery may suffice to return what has been lost to the people affected by this drug, they none the less deserve to be financially compensated. If you are in need of legal advice you should contact an attorney immediately. Many Benicar Lawyers provide free consultations.

If you are a law firm working with victims of Benicar and would like to add content to this website, please email us at info@masstortamerica.com or use our contact form.